Valuation Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
After hours 04:42:40 am | |||
| 218.70 USD | -0.32% |
|
225.79 | +3.24% |
| 20/07 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… |  |
| 13/07 | BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 | MT |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 10,534 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 5.1% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 12,348 | 11,919 | 11,538 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 3.37% | -3.47% | -3.2% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 35.7x | 23.9x | 22x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 3.19x | 2.85x | 2.59x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0.5x | 2.53x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 2.74x | 2.69x | 2.57x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 3.21x | 3.04x | 2.82x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 12.5x | 11.3x | 10.3x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 15.2x | 13.5x | 12.1x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 24x | 19.2x | 36.7x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 4.17% | 5.21% | 2.73% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 6.131 | 9.153 | 9.949 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,848 | 3,923 | 4,099 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 990.4 | 1,053 | 1,120 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 811.4 | 883.7 | 949.7 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 285.1 | 417.3 | 447 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 1,814 | 1,385 | 1,004 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 218.70 | 218.70 | 218.70 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 48,168 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | 19/02/25 | 18/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.79x | 3.22x | 12.5x | -.--% | 1.06TCr | |
| 34.06x | 5.97x | 18.46x | 0.97% | 4.85TCr | |
| -22.99x | 334.06x | -20.92x | -.--% | 3.9TCr | |
| 48.09x | 4.84x | 31.06x | -.--% | 3.54TCr | |
| 24.54x | 2.74x | 11.83x | -.--% | 3.37TCr | |
| 26.5x | 7.78x | 19.53x | 0.43% | 2.66TCr | |
| 31.4x | 5.06x | 23.02x | -.--% | 1.52TCr | |
| 23.86x | 2.05x | 9.01x | 1.1% | 1.39TCr | |
| 23.55x | 1.88x | 11.39x | -.--% | 1.28TCr | |
| Average | 24.98x | 40.84x | 12.87x | 0.28% | 2.62TCr | |
| Weighted average by Cap. | 23.25x | 59.19x | 12.10x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
